TY - JOUR
T1 - International BEAT-PCD consensus statement for infection prevention and control for primary ciliary dyskinesia in collaboration with ERN-LUNG PCD Core Network and patient representatives
AU - Marthin, June K.
AU - Lucas, Jane S.
AU - Boon, Mieke
AU - Casaulta, Carmen
AU - Crowley, Suzanne
AU - Destouches, Damien M.S.
AU - Eber, Ernst
AU - Escribano, Amparo
AU - Haarman, Eric
AU - Hogg, Claire
AU - Maitre, Bernard
AU - Marsh, Gemma
AU - Martinu, Vendula
AU - Moreno-Galdó, Antonio
AU - Mussaffi, Huda
AU - Omran, Heymut
AU - Pohunek, Petr
AU - Rindlisbacher, Bernhard
AU - Robinson, Phil
AU - Snijders, Deborah
AU - Walker, Woolf T.
AU - Yiallouros, Panayiotis
AU - Johansen, Helle Krogh
AU - Nielsen, Kim G.
N1 - Funding Information: Support statement: The BEAT-PCD network was initially funded by COST Action BM 1407, and now by European Respiratory Society Clinical Research Collaboration. Most participating researchers and contributors are participants in European Reference Network for Rare Respiratory Diseases (ERN-LUNG) project identification number 739546. Petr Pohunek and Vendula Martinu were supported by Ministry of Health of the Czech Republic grant number NV-19-07-00210. All rights reserved. First and last author were supported by The Lung Association, Denmark and Børnelungefonden. Funding information for this article has been deposited with the Crossref Funder Registry. Funding Information: Support statement: The BEAT-PCD network was initially funded by COST Action BM 1407, and now by European Respiratory Society Clinical Research Collaboration. Most participating researchers and contributors are participants in European Reference Network for Rare Respiratory Diseases (ERN-LUNG) project identification number 739546. Petr Pohunek and Vendula Martinu were supported by Ministry of Health of the Czech Republic grant number NV-19-07-00210. All rights reserved. First and last author were supported by The Lung Association, Denmark and Børnelungefonden. Publisher Copyright: © The authors 2021.
PY - 2021/7/1
Y1 - 2021/7/1
N2 - Introduction In primary ciliary dyskinesia (PCD) impaired mucociliary clearance leads to recurrent airway infections and progressive lung destruction, and concern over chronic airway infection and patient-to-patient transmission is considerable. So far, there has been no defined consensus on how to control infection across centres caring for patients with PCD. Within the BEAT-PCD network, COST Action and ERS CRC together with the ERN-Lung PCD core a first initiative has now been taken towards creating such a consensus statement. Methods A multidisciplinary international PCD expert panel was set up to create a consensus statement for infection prevention and control (IP&C) for PCD, covering diagnostic microbiology, infection prevention for specific pathogens considered indicated for treatment and segregation aspects. Using a modified Delphi process, consensus to a statement demanded at least 80% agreement within the PCD expert panel group. Patient organisation representatives were involved throughout the process. Results We present a consensus statement on 20 IP&C statements for PCD including suggested actions for microbiological identification, indications for treatment of Pseudomonas aeruginosa, Burkholderia cepacia and nontuberculous mycobacteria and suggested segregation aspects aimed to minimise patient-to-patient transmission of infections whether in-hospital, in PCD clinics or wards, or out of hospital at meetings between people with PCD. The statement also includes segregation aspects adapted to the current coronavirus disease 2019 (COVID-19) pandemic. Conclusion The first ever international consensus statement on IP&C intended specifically for PCD is presented and is targeted at clinicians managing paediatric and adult patients with PCD, microbiologists, patient organisations and not least the patients and their families.
AB - Introduction In primary ciliary dyskinesia (PCD) impaired mucociliary clearance leads to recurrent airway infections and progressive lung destruction, and concern over chronic airway infection and patient-to-patient transmission is considerable. So far, there has been no defined consensus on how to control infection across centres caring for patients with PCD. Within the BEAT-PCD network, COST Action and ERS CRC together with the ERN-Lung PCD core a first initiative has now been taken towards creating such a consensus statement. Methods A multidisciplinary international PCD expert panel was set up to create a consensus statement for infection prevention and control (IP&C) for PCD, covering diagnostic microbiology, infection prevention for specific pathogens considered indicated for treatment and segregation aspects. Using a modified Delphi process, consensus to a statement demanded at least 80% agreement within the PCD expert panel group. Patient organisation representatives were involved throughout the process. Results We present a consensus statement on 20 IP&C statements for PCD including suggested actions for microbiological identification, indications for treatment of Pseudomonas aeruginosa, Burkholderia cepacia and nontuberculous mycobacteria and suggested segregation aspects aimed to minimise patient-to-patient transmission of infections whether in-hospital, in PCD clinics or wards, or out of hospital at meetings between people with PCD. The statement also includes segregation aspects adapted to the current coronavirus disease 2019 (COVID-19) pandemic. Conclusion The first ever international consensus statement on IP&C intended specifically for PCD is presented and is targeted at clinicians managing paediatric and adult patients with PCD, microbiologists, patient organisations and not least the patients and their families.
UR - http://www.scopus.com/inward/record.url?scp=85114608765&partnerID=8YFLogxK
U2 - https://doi.org/10.1183/23120541.00301-2021
DO - https://doi.org/10.1183/23120541.00301-2021
M3 - Article
C2 - 34350277
SN - 2312-0541
VL - 7
JO - ERJ open research
JF - ERJ open research
IS - 3
M1 - 00301-2021
ER -